On 28 April 2026, True Corporation, the Thai telecommunications subsidiary of C.P. Group, announced a clinical pilot partnership with Shanghai-based OYMotion. The partnership integrates OYMotion’s brain-computer interface and electromyography decoding technology with True’s 5G network and Thai medical-channel relationships for neuro-rehabilitation deployment. On 29 April, C.P. Group Innovation led the $55 million Series A round for US-based Axoft Inc. The two announcements, within 24 hours of each other, place Thailand at the centre of an emerging Southeast Asian brain-computer interface commercial corridor, with C.P. Group now positioned across both Western and Chinese BCI capability inside the country through different mechanisms in each case.
The two positions are not equivalent in structure. The Axoft placement is a direct equity investment, with C.P. Group Innovation as lead investor alongside Alumni Ventures, the Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. The OYMotion relationship is a commercial partnership routed through True Corporation, with no disclosed C.P. Group equity in OYMotion itself. The Thai conglomerate is using equity for US-based capability and commercial partnership for Chinese capability, a pattern that aligns with the structural difficulty foreign investors face taking direct equity positions in Chinese BCI companies under China’s 2024 Foreign Investment Negative List restrictions on adjacent cell, gene therapy, and biomedical technology categories.
The OYMotion-True partnership
OYMotion was founded in Shanghai in 2015 and holds both US FDA and CE certifications across its electromyography sensing, neural rehabilitation exoskeleton, and smart bionic hand product lines. The True Corporation partnership announced on 28 April brings OYMotion’s neural signal decoding into Thai hospitals via True’s 5G network infrastructure. Pilots are currently underway at leading Thai hospitals to validate clinical efficacy ahead of broader rollout across the public health network. The framing is stroke recovery, movement disorders, and disability rehabilitation indications common across Southeast Asia.
OYMotion completed a Series C1 round of approximately 150 million yuan, or $20 million USD, on 26 March 2026, led by the Shenzhen Brain Science and Brain-Like Intelligence Industry Investment Fund under CICC Capital. The CICC Brain Science Fund reports the OYMotion placement as its first investment. OYMotion has also previously received capital from Sanbo Brain Science Group and Tianjin Heying Capital, making the company one of the few Chinese BCI players backed by multiple specialised brain science investment vehicles. The Industrial Builder posture the Dargentic Neurotechnology Report (Spring 2026) maps for China on Page 18 is now operating internationally through this commercial-partnership channel rather than through cross-border equity placement.
The Axoft Series A
C.P. Group Innovation led Axoft’s $55 million Series A on 29 April 2026 alongside Alumni Ventures, Stanford President’s Venture Fund, Hillhouse Investment, and Gaorong Ventures. Axoft is a US-based implantable brain-computer interface company building its Fleuron-material iBCI platform, which the company describes as up to 10,000 times softer than the polyimide used in existing iBCI products. Axoft has completed first-in-human clinical trials in more than 11 patients worldwide as of the Series A announcement. The capital is supporting global clinical trial expansion, progression toward US regulatory approval, and construction of a good manufacturing practice facility.
The Hillhouse Investment and Gaorong Ventures participation in the Axoft Series A is worth noting. Chinese capital is already inside the Western BCI cohort that C.P. Group Innovation has taken equity exposure to, which complicates any clean Western-versus-Chinese capital geography reading of the BCI sector.
Thailand’s three-layer commercial position
Thailand is building a BCI commercial position across three distinct layers at the same time. The state layer is Thailand’s roughly $15 billion AI and quantum capability push, prioritised through the country’s Board of Investment framework as a strategic technology sector. The corporate layer is C.P. Group, with the two-track positioning described above through C.P. Group Innovation on the equity side and True Corporation on the commercial-partnership side. The clinical layer is the resulting flow of BCI capability into Thai hospitals, with OYMotion’s rehabilitation pilots now active in leading Thai facilities and Axoft’s global clinical trial expansion partly funded by Thai capital.
Thailand has no domestic FDA-cleared BCI company, no major sovereign BCI equity placement, and no existing BCI industrial base. What it has, through C.P. Group, is financing infrastructure on one side and commercial-channel infrastructure on the other to host both Western and Chinese BCI capability inside its borders.
What this means for Southeast Asian neurotech
No other Southeast Asian country has visibly assembled comparable BCI commercial infrastructure as of May 2026. Singapore’s sovereign capital vehicles, Temasek and GIC, have made no visible BCI placements. The other major Southeast Asian economies have not surfaced equivalent corporate or sovereign positions in the category. Thailand, through C.P. Group rather than the sovereign wealth layer, has assembled the only visible Southeast Asian BCI commercial corridor with both US and Chinese capability operating inside its borders.
The competitive question for the rest of the region is whether to replicate Thailand’s model with a different connecting node, or accept that Southeast Asian BCI clinical infrastructure will concentrate in Bangkok. The OYMotion-True pilot results, expected to start producing clinical efficacy data later in 2026, will be the first test of whether the Thai hub thesis is delivering operational outcomes or remains a positioning play.
What to watch
Three signals over the next twelve months will determine whether Thailand’s BCI commercial position consolidates or fragments. The first is the pilot deployment timeline for the OYMotion-True partnership at Thai hospitals, including which specific hospitals receive the technology, which therapeutic indications are covered first, and how rapidly the rollout moves from pilot to standard-of-care. The second is whether other Chinese BCI players follow OYMotion’s Thailand template, with NeuroXess, BrainCo, NeuCyber, or StairMed as plausible candidates to bring commercial expansion into Southeast Asia next. The third is whether C.P. Group Innovation makes additional direct BCI equity placements beyond Axoft, particularly into the European cohort that includes INBRAIN, ONWARD, and CorTec, which would add a third regional source of BCI capability to Thailand’s positioning.
Sources: Axoft $55M Series A led by C.P. Group Innovation — BusinessWire, 29 April 2026. True Corporation × OYMotion partnership — Bangkok Post. OYMotion Thailand expansion — Gasgoo, 10 May 2026. OYMotion Series C1 led by CICC Brain Science Fund — Gasgoo. True Corporation as C.P. Group subsidiary — Wikipedia.